US EditionPublished • loading... • Updated
Neuronata-R® Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway
- Neuronata-R® showed meaningful efficacy in patients with slower disease progression, confirming its potential to preserve function and respiratory capacity in ALS.
- The findings indicate a strong link between neuroprotection, as shown by sustained reductions in neurofilament light chain and MCP-1, and clinical outcomes.
- CorestemChemon plans to submit a Biologics License Application within 2026, seeking an accelerated approval pathway aligned with prior ALS treatments.
Insights by Ground AI
58 Articles
58 Articles
Bennington Banner+56 Reposted by 56 other sources
Neuronata-R® Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway
Meaningful improvements confirmed in slow-progressor subgroup; biomarker reductions support precision-medicine approach and potential FDA accelerated pathway
CorestemChemon Reports Phase 3 Trial Data Showing Neuronata-R Improves Outcomes in ALS Slow Progressors
CorestemChemon Inc. has presented findings from its Pha […] The post CorestemChemon Reports Phase 3 Trial Data Showing Neuronata-R Improves Outcomes in ALS Slow Progressors first appeared on GeneOnline News. The post CorestemChemon Reports Phase 3 Trial Data Showing Neuronata-R Improves Outcomes in ALS Slow Progressors appeared first on GeneOnline News.
Coverage Details
Total News Sources58
Leaning Left8Leaning Right3Center20Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
L 26%
C 65%
Factuality
To view factuality data please Upgrade to Premium
